Rayonier Advanced Materials (RYAM) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Initiated a formal review of strategic alternatives, including potential sale, merger, partnership, or capital structure actions, with Morgan Stanley as advisor; interim office of the CEO established and search for permanent CEO underway.
Net sales for Q1 2026 were $319 million, down year-over-year due to lower volumes and pricing in key segments.
Net loss attributable to shareholders was $81.6 million, including $41 million in non-cash charges from the permanent idling of the Temiscaming HPC plant.
Adjusted EBITDA was $8 million, with positive adjusted free cash flow of $12 million.
The company reorganized into two segments: High Purity Cellulose and Paperboard & High Yield Pulp.
Financial highlights
Q1 2026 net sales were $319 million, adjusted EBITDA was $8 million, and net loss was $81 million.
High Purity Cellulose generated $24 million of adjusted EBITDA; Paperboard & High Yield Pulp posted $(5) million.
Adjusted Free Cash Flow improved to $12 million from $2 million in the prior year quarter.
Cash and cash equivalents stood at $68 million; total liquidity at quarter-end was $160 million.
Debt to capital ratio increased to 77% from 71% at year-end 2025; total debt stood at $763 million.
Outlook and guidance
2026 is a transition year, with sequential improvement and positive free cash flow anticipated; full-year EBITDA expected to exceed 2025.
Targeting improved mix and EBITDA growth across all businesses, with new product commercialization expected to benefit results.
High Purity Cellulose expects improved pricing and higher CC volumes, but lower CS volumes for 2026.
Paperboard & High Yield Pulp segment anticipates year-over-year improvement from new products and market expansion.
Capital expenditures for 2026 forecasted at $80–$85 million, with a focus on cash generation and deleveraging.
Latest events from Rayonier Advanced Materials
- Director nominee resigned; votes for this nominee won't count, all other matters unchanged.RYAM
Proxy filing24 Apr 2026 - Board refresh, executive pay alignment, and governance reforms headline this year's proxy.RYAM
Proxy filing30 Mar 2026 - Key votes include board declassification, supermajority removal, and executive pay approval.RYAM
Proxy filing30 Mar 2026 - Board refresh, CEO change, and governance reforms highlight a focus on accountability and performance.RYAM
Proxy filing20 Mar 2026 - 2026 targets positive cash flow, EBITDA growth, and new product launches amid disciplined execution.RYAM
Gabelli Funds Annual Specialty Chemicals Symposium20 Mar 2026 - 2025 results showed lower revenue and EBITDA, with 2026 targeting free cash flow recovery.RYAM
Q4 20254 Mar 2026 - Aiming to double EBITDA by 2027, leveraging price, cost, and biomaterials growth.RYAM
17th Annual Southwest IDEAS Conference3 Feb 2026 - Transformation to specialty cellulose, innovation, and sustainability drive growth and profitability.RYAM
Fireside Chat3 Feb 2026 - Shifting to specialty cellulose and biomaterials, with debt reduction and margin expansion in focus.RYAM
Small-Cap Growth Virtual Investor Conference3 Feb 2026